Skip to main content
SpringerLink
Log in

Corticosteroids are still the mainstay for treating relapses of Crohn’s disease, but should not be used for maintenance therapy

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Irrespective of their local and systemic adverse effects, conventional corticosteroids remain the foundation of therapy for induction of clinical remission in patients with Crohn’s disease because of their prompt onset of action and effectiveness. However, they are not recommended as maintenance therapy because of their lack of efficacy in maintaining remission and potential to cause systemic adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vavricka SR, Schoepfer AM, Scharl M, et al. Steroid use in Crohn’s disease. Drugs. 2014;74(3):313–24.

    Article  PubMed  CAS  Google Scholar 

  2. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. BMJ. 1955;2(4947):1041–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology. 1979;77(4 Pt 2):847–69.

    PubMed  CAS  Google Scholar 

  4. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology. 1984;86(2):249–66.

    PubMed  CAS  Google Scholar 

  5. Martin FSL, Beck IT, Anderson AH, et al. Oral 5-ASA versus prednisone in short term treatment of Crohn’s disease: a multicentre controlled trial. Can J Gastroenterol. 1990;4:452–7.

    Google Scholar 

  6. Gross V, Andus T, Fischbach W, et al. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn’s ileocolitis: a multicenter randomized double-blind study. German 5-ASA Study Group. Z Gastroenterol. 1995;33(10):581–4.

    PubMed  CAS  Google Scholar 

  7. Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn’s ileitis: results of a randomized, multicenter trial. Gastroenterology. 1999;116(3):521–6.

    Article  PubMed  CAS  Google Scholar 

  8. Mayberry JF, Lobo A, Ford AC, et al. NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people. Aliment Pharmacol Ther. 2013;37(2):195–203.

    Article  PubMed  CAS  Google Scholar 

  9. Keenan GF. Management of complications of glucocorticoid therapy. Clin Chest Med. 1997;18(3):507–20.

    Article  PubMed  CAS  Google Scholar 

  10. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621–30.

    Article  PubMed  CAS  Google Scholar 

  11. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2001;96(3):635–43.

    Article  PubMed  CAS  Google Scholar 

  12. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2003;(4):CD000301.

  13. Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;(3):CD000296.

  14. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4(1):28–62.

    Article  PubMed  CAS  Google Scholar 

  15. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130(3):940–87.

    Article  PubMed  CAS  Google Scholar 

  16. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn’s disease: Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331(13):836–41.

    Article  PubMed  CAS  Google Scholar 

  17. Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97(7):1748–54.

    Article  PubMed  CAS  Google Scholar 

  18. Thomsen OO, Cortot A, Jewell D, et al. A comparison of budesonide and mesalamine for active Crohn’s disease: International Budesonide-Mesalamine Study Group. N Engl J Med. 1998;339(6):370–4.

    Article  PubMed  CAS  Google Scholar 

  19. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med. 1994;331(13):842–5.

    Article  PubMed  CAS  Google Scholar 

  20. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease: the Global Budesonide Study Group. Gut. 1997;41(2):209–14.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology. 1996;110(1):45–51.

    Article  PubMed  CAS  Google Scholar 

  22. Lofberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 1996;110(6):1713–8.

    Article  PubMed  CAS  Google Scholar 

  23. Ferguson A, Campieri M, Doe W, et al. Oral budesonide as maintenance therapy in Crohn’s disease: results of a 12-month study. Global Budesonide Study Group. Aliment Pharmacol Ther. 1998;12(2):175–83.

    Article  PubMed  CAS  Google Scholar 

  24. Benchimol EI, Seow CH, Otley AR, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2009;(1):CD002913.

  25. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:590–9.

    Article  PubMed  CAS  Google Scholar 

  26. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2010;(6):CD000545.

  27. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.

    Article  PubMed  CAS  Google Scholar 

  28. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

This article was adapted from Drugs 2014;74(3):313-24 [1]. The preparation of this article was not supported by any external funding. The preparation of the original article [1] was supported by grants from the Swiss National Science Foundation and University of Zurich.

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Corticosteroids are still the mainstay for treating relapses of Crohn’s disease, but should not be used for maintenance therapy. Drugs Ther Perspect 30, 348–351 (2014). https://doi.org/10.1007/s40267-014-0146-0

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-014-0146-0

    Search

    Navigation